Immunovant Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immunovant Inc (IMVT)
Immunovant Inc stock price live, this page displays NASDAQ IMVT stock exchange data. View the IMVT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immunovant Inc real time stock price chart below.
What Is the Immunovant Inc Stock Price Today?
The Immunovant Inc stock price today is 26.03.
What Is the Stock Symbol for Immunovant Inc?
The stock symbol for Immunovant Inc is "IMVT."
What Stock Exchange Does Immunovant Inc Trade On?
Immunovant Inc is listed and trades on the NASDAQ stock exchange.
Is Immunovant Inc a Good Stock to Buy?
Determining whether Immunovant Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMVT quote. (ISIN: US45258J1025)
What Is the Immunovant Inc Stock Price Today?
The Immunovant Inc stock price today is 26.03.
What Is the Stock Symbol for Immunovant Inc?
The stock symbol for Immunovant Inc is "IMVT."
What Stock Exchange Does Immunovant Inc Trade On?
Immunovant Inc is listed and trades on the NASDAQ stock exchange.
Is Immunovant Inc a Good Stock to Buy?
Determining whether Immunovant Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMVT quote. (ISIN: US45258J1025)
26.03
+1.97(+8.17%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.85
26.88
52 wk Range
12.72
27.80
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.8526.88
52 wk Range
12.7227.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMVT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
40.31
Upside
+54.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 10Q Immunovant Inc For: 6 February
- Investing.com
- Immunovant Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 10Q Immunovant Inc For: 6 February
- Investing.com
- Form 8K Immunovant Inc For: 6 February
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Immunovant Inc Company Profile
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant Inc SWOT Analysis
Pioneering Treatment | Immunovant's novel anti-FcRn therapy shows promise for autoimmune diseases, particularly Graves' disease, with potential for best-in-class efficacy |
Market Potential | Explore the substantial opportunity in Graves' disease, with an estimated 20,000 high-need patients diagnosed annually in the US |
Analyst Optimism | Price targets range from $36 to $58, suggesting significant upside potential despite recent stock decline. Average target stands at $57 |
Strategic Expansion | Delve into Immunovant's ambitious plan to target 10 indications by 2026, diversifying risk and expanding market potential |
Immunovant Inc Earnings Call Summary for Q3/2026
- Immunovant exceeded Q3 2026 EPS expectations with -0.61 vs -0.72 forecast, triggering an 8.35% premarket stock surge to $26.07
- Strong financial position with $4.5 billion in consolidated cash to fund operations, despite reporting a non-GAAP net loss of $167 million
- Phase 2 results for Brepocitinib in cutaneous sarcoidosis showed promising outcomes, with CEO Matt Gline noting the drug 'has done everything we could have asked for'
- Company anticipates multiple pivotal study readouts and projects commercial launch for Graves' disease treatment by end of 2028
- Potential risks include market competition, ongoing litigation against Moderna, regulatory hurdles, and economic fluctuations affecting funding strategies
Last Updated: 2026-02-06, 09:34 a/m
Read Full TranscriptCompare IMVT to Peers and Sector
Metrics to compare | IMVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −1.5x | −0.5x | |
PEG Ratio | 0.40 | 0.09 | 0.00 | |
Price/Book | 9.8x | 5.6x | 2.6x | |
Price / LTM Sales | - | 9.2x | 3.3x | |
Upside (Analyst Target) | 68.6% | 52.3% | 48.1% | |
Fair Value Upside | Unlock | 8.2% | 7.7% | Unlock |
Analyst Ratings
13 Buy
4 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 40.31
(+54.87% Upside)
Earnings
Latest Release
Feb 06, 2026
EPS / Forecast
-0.61 / -0.72
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Immunovant (IMVT) Stock Price Today?
The Immunovant stock price today is 26.03
What Stock Exchange Does Immunovant Trade On?
Immunovant is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immunovant?
The stock symbol for Immunovant is "IMVT."
What Is the Immunovant Market Cap?
As of today, Immunovant market cap is 5.25B.
What Is Immunovant's Earnings Per Share (TTM)?
The Immunovant EPS (TTM) is -2.82.
When Is the Next Immunovant Earnings Date?
Immunovant will release its next earnings report on Feb 06, 2026.
From a Technical Analysis Perspective, Is IMVT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Immunovant Stock Split?
Immunovant has split 0 times.
How Many Employees Does Immunovant Have?
Immunovant has 362 employees.
What is the current trading status of Immunovant (IMVT)?
As of Feb 06, 2026, Immunovant (IMVT) is trading at a price of 26.03, with a previous close of 24.06. The stock has fluctuated within a day range of 24.85 to 26.88, while its 52-week range spans from 12.72 to 27.80.
What Is Immunovant (IMVT) Price Target According to Analysts?
The average 12-month price target for Immunovant is USD40.31, with a high estimate of USD57 and a low estimate of USD16. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +54.87% Upside potential.
What Is the IMVT Premarket Price?
IMVT's last pre-market stock price is 26.07. The pre-market share volume is 540.00, and the stock has decreased by 2.01, or 8.35%.
What Is the IMVT After Hours Price?
IMVT's last after hours stock price is 24.07, the stock has decreased by 0.01, or 0.04%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.